



**AHEAD OF THE HERD.COM**

Telling you things everyone else doesn't already know.

## **Sernova to employ glucose monitoring system in upcoming clinical trial**

*As a general rule, the most successful man in life is the man who has the best information*

Sernova Corp (TSXV:SVA) continues to make progress on its US human clinical trial for Type 1 diabetes, [announcing on Feb. 22](#) that continuous glucose monitoring systems (CGM) will be provided to patients that are enrolled in the trial. CGM will allow Sernova to track the function of the therapeutic cells in order to take key efficacy measurements – including glucose variability and hypoglycemia duration - at multiple time points after the cells are transplanted into the Cell Pouch. The measurements are taken by connecting a glucose sensor, placed inside the body, to a pager-sized monitoring device that stores glucose data over a six-day period.

“We believe continuous glucose monitoring of patients may be an important and sensitive method to closely track the function of the transplanted therapeutic cells within the Cell Pouch,” said Dr. Philip Toleikis, Sernova’s president and CEO. “We are pleased with our collaborators in this study who have shown the foresight to support Type 1 diabetes patients seeking treatment via next-generation regenerative medicine technologies.”

From Wikipedia regarding SVA’s CGM supplier - Medtronic is among the world's largest medical equipment development companies. In 2015, at the time of its acquisition of Covidien, its market capitalisation was about \$100 billion. Medtronic operates in more than 140 countries. It employs over 85,000 people and has more than 53,000 patents.

The diabetes trial, approved by the FDA in December, is a major milestone for Sernova, which has been developing the Cell Pouch since 2009. The device is essentially an implanted housing vehicle for therapeutic cells that produce and deliver insulin, as needed. [Read more about the Cell Pouch and the clinical trial here](#)

Echelon Wealth Partners, on February 12<sup>th</sup>, put out an analyst report formally shifting their Sernova (SVA-V) rating from an idea of interest to a Speculative BUY, with a one-year price target of \$1.00

More good news for Sernova came this week in the form of a note by Mackie Research which put the Ontario-based regenerative medicine company on its watch list. The note advises subscribers to keep SVA on their radar screens “because at some point over the next year it’s likely to accelerate rapidly on a major breakout.” Mackie notes that the stock hit a 10-year high of 51 cents a share on Jan. 3, and sees a major move to the upside once the shares break through resistance in the low-\$0.50s.

## **Conclusion**

Is a leader in the regenerative medicine space on your radar screen? I can guarantee you SVA is on mine.

If it isn’t, maybe it should be?

Richard (Rick) Mills

[aheadoftheherd.com](http://aheadoftheherd.com)

Just read, or participate in if you wish, our free [Investors forums](#).

Ahead of the Herd is now on [Twitter](#).

[Newsletter Archives](#).

Legal Notice / Disclaimer

This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment.

Richard Mills owns shares in Sernova Corp (TSX.V:SVA).